ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended

Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

Maine - November 13, 2024 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"),

a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the

health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September

preliminary, unaudited product sales for the third quarter of 2024 were first reported on October 8, 2024," commented Michael F.

Brigham, President and CEO of ImmuCell. "We have no changes to those figures."

are excited about our sales growth compared to the prior periods," continued Mr. Brigham. "We have operated without another

contamination event since April of 2024, which leads us to believe that the remediation steps that we have implemented in our production

process are keeping the bioburden within specification. Now, we are focused on fixing our process yields to improve our gross margin."

have improved our cash position during 2024 pursuant to an at the market offering at the expense of some stockholder ownership dilution,"

continued Mr. Brigham. "We think this has been necessary to advance our strategic plan, which includes continuing to provide First

Defense to the market as we stabilize our production systems at a higher output level

and revolutionizing the way that subclinical mastitis is treated in today's dairy market with Re-Tain ,

our novel alternative to traditional antibiotics that is in the FDA approval process."

continue to work to achieve FDA approval to commercialize Re-Tain ," concluded Mr. Brigham. "We plan

to provide an update when we have filed our Non-Administrative NADA, which will include our fourth submission of the CMC Technical Section,

responding to the minor issues from the Incomplete Letter issued in May of 2024, together with All Other Information and Product Labeling.

We anticipate making this submission shortly after the inspectional observations at our contract manufacturer are resolved to the satisfaction

of the FDA. We have been in discussions with the FDA to seek an expedited review once that submission is made."

Sheet Data as of September 30, 2024:

Note Regarding Forward-Looking Statements (Safe Harbor Statement):

Press Release and the statements to be made in the related conference call referenced herein contain "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified

by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects",

"may", "anticipates", "aims", "intends", "would", "could", "should",

"will", "plans", "believes", "estimates", "targets", "projects",

"forecasts", "seeks" and similar words and expressions. Such statements include, but are not limited to, any

forward-looking statements relating to: our plans and strategies for our business; projections of future financial or operational performance;

the timing and outcome of pending or anticipated applications for regulatory approvals; future demand for our products; the scope and

timing of ongoing and future product development work and commercialization of our products; future costs of product development efforts;

the expected efficacy of new products; estimates about the market size for our products; future market share of and revenue generated

by current products and products still in development; our ability to increase production output and reduce costs of goods sold per unit;

the adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand

for our products on a timely basis; the likelihood, severity or impact of future contamination events; the robustness of our manufacturing

processes and related technical issues; estimates about our production capacity, efficiency and yield; the salability of products currently

held in inventory pending FDA approval; future regulatory requirements relating to our products; future expense ratios and margins; the

effectiveness of our investments in our business; anticipated changes in our manufacturing capabilities and efficiencies; our effectiveness

in competing against competitors within both our existing and our anticipated product markets; our ability to convert the backlog of

orders into sales; and any other statements that are not historical facts. These statements are intended to provide management's

current expectation of future events as of the date of this press release, are based on management's estimates, projections, beliefs

and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks

and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially

different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties

relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including

the First Defense product line and Re-Tain ), competition within our anticipated product

markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and

product demand (including the consequences of backlogs), uncertainty associated with the timing and volume of customer orders as we come

out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer and supplier relationships, commercial

and operational risks relating to our current and planned expansion of production capacity, and other risks and uncertainties detailed

from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q,

our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on

our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that

future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking

statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or

Statements of Operations (Unaudited)

Balance Sheet Data (In thousands) (Unaudited)

a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes

or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance

with GAAP. The non-GAAP measures included in this press release should be considered in addition to, and not as a substitute for or superior

to, the comparable measure prepared in accordance with GAAP. We believe that considering the non-GAAP measure of Earnings Before Interest,

Taxes, Depreciation and Amortization (EBITDA) assists management and investors by looking at our performance across reporting periods

on a consistent basis excluding these certain charges that are not uses of cash from our reported loss before income taxes. We calculate

EBITDA as described in the following table:

stock-based compensation expense (which is a non-cash expense that management adds back to EBITDA when assessing its cash flows) of approximately

$78,000 and $96,000 during the three-month periods ended September 30, 2024 and 2023 and $257,000 and $268,000 during the nine-month

periods ended September 30, 2024, and 2023, respectively. Cash payments to satisfy debt repayment obligations or to make capital expenditure

investments are other uses of cash that are not included in the calculation of EBITDA, which management also considers when assessing

The Company is planning to host a conference call on Thursday, November 14, 2024 at 9:00 AM ET to discuss the unaudited financial results

for the quarter ended September 30, 2024. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or

(412) 317-5499 (international). A teleconference replay of the call will be available until November 21, 2024 at (877) 344-7529 (toll

free) or (412) 317-0088 (international), utilizing replay access code #6807288. Investors are encouraged to review the Company's

updated Corporate Presentation slide deck that provides an overview of the Company's business and is available under the "Investors"

tab of the Company's website at www.immucell.com, or by request to the Company. An updated version of the slide deck will be made

available under the "Investors" tab of the Company's website after the market closes on Wednesday, November 13, 2024.

Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and

productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense , providing Immediate

Immunity to newborn dairy and beef calves, and is in the late stages of developing Re-Tain , a novel

treatment for subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold label restrictions that provides

an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.

Diaz, Robert Blum and Joe Dorame

Lytham Partners, LLC